From our, non-expert view, that would solve the funding problem, saves director fees and who knows what other expenses. But Hopper obviously wants to keep the 3 comps separated for a variety of reasons.
The advantage would be he could put any value on CHM he wants as he and Lesley Russel are directors of both. The 2 excuse themselves from voting and the others just follow Hopper's " Recommendation". He could do from 1 for 1 to even 5 IMU for 1 CHM which would benefit all CHM holders. At IMU he would have 2 shots on the solid cancer goal, CDH17 directly and CF33 / CD19 / CD19-CAR-T indirectly. Plus the advanced GBM and AML soon to be rego trial assets. That would give IMU possibly 4-5 FDA approved drugs over the next 2 years.
And again the question, why deliberately taking CHM to the edge when everyone in the science world is praising the data and the outlook. Doesn't make any sense.
COV and BDX, cancer diagnostics, having a great day. There is heaps of BIO-Tech money out there and Hopper refuses to pick it up. Why?????????????
GLTA
CHM Price at posting:
1.9¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)